Amicus Therapeutics, Inc. company was founded in 2002 and is based in Cranbury, New Jersey. Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company’s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

Sepracor Inc. company focuses its drug development efforts in two main therapeutic categories: respiratory and central nervous system (CNS) disorders. Its marketed products include asthma drug Xopenex, insomnia therapy Lunesta, and chronic obstructive pulmonary disease (COPD) treatment Brovana. Sepracor markets its products to primary care physicians and some specialists in the US; it also has some limited operations in Canada. It has licensed international development and commercialization rights for Lunesta to Eisai and GlaxoSmithKline. Sepracor was acquired for $2.6 billion by Japanese firm Dainippon Sumitomo Pharma in 2009.

New Leaf Brands, Inc. engages in the development, marketing, and distribution of ready-to-drink (RTD) beverages. Products The company’s New Leaf brand is a natural tea sweetened with organic cane sugar and specifically formulated to address the market for a healthy but appealing beverage. New Leaf is available in 13 flavors, integrating blue teas, green teas, black teas, and white teas. New Leaf products consist of Blue Teas, such as Diet Blue Tea with Lemon, Diet Blue Tea with Peach, Blue Tea with Lemon, Blue Tea with Peach, and Blue Tea with Raspberry; Green Teas, such as Green Tea with Plum, Green Tea with Ginseng, and Green Tea with Mango; White Teas, such as White Tea with Ginseng & Honey, White Tea with Honey Dew Melon, White Tea with Strawberry, and White Tea with Tangerine; and Black Tea: Mint & Lime International Sales The company sells its New Leaf brands in Canada and the Carribean. Customers New Leaf Tea is marketed to distributors, such as natural food, gourmet food, and mainstream distributors. The company’s major distributor is Manhattan Beer. Competition The company competes with soft drink companies, such as Coca Cola, Pepsi, and Cadbury Schweppes. In addition, it competes with beverage companies, including Arizona, Snapple, Lipton Brisk, Sobe, Vitamin Water, Fuze, Nestea, Tazo, Honest Tea, and Sweet Leaf Tea. Dispositions On October 9, 2009, the company completed the sale of its nutraceutical business, Nutritional Specialties, Inc. History The company was incorporated in 1986. It was formerly known as Baywood International, Inc. and changed its name to New Leaf Brands, Inc. on October 19, 2009.

BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal treatment, as well as herbal remedies, vitamins and adjunctive therapies. Through its wholly owned subsidiary, AXM Pharma Shenyang, Inc., the Company has established a pharmaceutical operation focused on supplying the drugs and branded products in specific categories. Werke Pharmaceuticals, Inc. is the Company’s wholly owned subsidiary, which owns 100% of AXM Pharma Shenyang Inc., a wholly foreign owned enterprise (WFOE). Its product portfolio includes Asarone injectibles solution, Weifukang and Lifupeng. Weifukang is an antiseptic cream for cleansing acne and for relieving the symptoms of eczema, psoriasis and other skin irritations, such as contact dermatitis. Lifupeng (Rifampicin) is used for treatment of tuberculosis.

CEO Samuel Bogoch founded Oncolab shortly after he discovered the technology for detecting anti-malignin antibodies in the 1960s. Oncolab, Inc. company makes the AMAS test, an early warning blood screening test for cancer. The test detects abnormal levels of anti-malignin antibody which may indicate the presence of tumors. It is the first antibody that can be directly related to the survival of cancer patients and can be easily detected even before malignin reaches a detectable level. The test is shipped for free and is administered by doctors, then sent to Oncolab to process the results (for a fee); there are also a handful of lab locations that administer the test.

Metagenics, Inc., doing business as Ethical Nutrients, manufactures and distributes medical foods and nutraceuticals to healthcare practitioners. The company offers FirstLine Therapy programs for the prevention and management of chronic conditions, including diabetes, cardiovascular disease, and arthritis. It distributes its products in North America, South America, Europe, and Asia. The company was founded in 1983 and is headquartered in San Clemente, California with research and development centers in Gig Harbor, Washington; and Ithaca, New York. It has manufacturing facilities in Gig Harbor, Washington. As of September 11, 2009, Metagenics, Inc. operates as a subsidiary of Alticor Inc.

China-Biotics, Inc. is engaged in the research, development, production, marketing and distribution of probiotics products, which are products that contain live microbial food supplements, which beneficially affect the host by improving its intestinal microbial balance. The Company manufactures and sells several health supplements under the Shining brand in the Shanghai area. It has four major products: Shining Essence, Shining Signal, Shining Golden Shield and Shining Energy. Shining Essence is composed of lactobacillus acidophilus and bifidobacterium bifidum, which is focused on balancing the microecology of the digestive system. Shining Signal is composed of monascus rice and lactobacillus acidophilus, focused on reducing high-blood pressure, high-blood sugar level and hyperlipidemia. Shining Golden Shield is composed of bifidobacterium adolescentis and lentinusedodes. Shining Energy is composed of Vitamin C, L. Arginine, and other amino acids.

Endo Pharmaceuticals Holdings Inc. was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania. Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company's products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company's generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited.

Astellas Pharma US, Inc. company's primary products include organ transplant immunosuppressant Prograf, overactive bladder treatment VESIcare, and vascular dilator Andenoscan. It is focusing its efforts on the following therapeutic areas: cardiology, dermatology, immunology, infectious diseases, and urology. The company's other products include antifungals Mycamine and AmBisome, enlarged prostate treatment Flomax, and dermatological product Protopic. Astellas Pharma US is a subsidiary of Astellas Pharma, which was formed in 2005 with the merger of Japan-based pharmaceutical companies Yamanouchi and Fujisawa.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.